A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The following is a summary of "Variations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy ...

This guide will walk you through the causes of PAD, the symptoms to watch out for, and most importantly, effective peripheral arterial disease treatment in Houston. Whether you’re dealing with PAD ...